PBAC's latest decision on Tetracosactide: Deferred (2021). Considered for Treatment of hypsarrhythmia and/or infantile spasms, and acute exacerbations in patients suffering from multiple sclerosis.
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2021
Submissions
2
2021 → 2021
Eligible population
Patients with hypsarrhythmia and/or infantile spasms, and patients with multiple sclerosis requiring acute exacerbation treatment.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
No ICER calculated. Cost plus analysis was used as the basis of economic evaluation, which the PBAC considered outdated and not referenced in current PBAC Guidelines. As a minor submission, economic analysis was not independently evaluated.